Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 947

1.

The intra-tumoural stroma in patients with breast cancer increases with age.

Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, Rakha EA, Green AR, Tollenaar RAEM, Mesker WE.

Breast Cancer Res Treat. 2019 Sep 18. doi: 10.1007/s10549-019-05422-6. [Epub ahead of print]

PMID:
31535319
2.

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills RK, Russell NH, Osborne CS, Papaemmanuil E, Gottgens B, Campbell PJ, Huntly BJP.

Blood. 2019 Sep 12. pii: blood.2019001553. doi: 10.1182/blood.2019001553. [Epub ahead of print]

PMID:
31515253
3.

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.

Ziliotto S, Gee JMW, Ellis IO, Green AR, Finlay P, Gobbato A, Taylor KM.

Metallomics. 2019 Sep 1;11(9):1579-1592. doi: 10.1039/c9mt00136k. Epub 2019 Sep 4.

PMID:
31483418
4.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Aug 30. doi: 10.1007/s10549-019-05420-8. [Epub ahead of print]

PMID:
31471836
5.

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.

Abdel-Fatah TMA, Ali R, Sadiq M, Moseley PM, Mesquita KA, Ball G, Green AR, Rakha EA, Chan SYT, Madhusudan S.

Cancers (Basel). 2019 Aug 10;11(8). pii: E1149. doi: 10.3390/cancers11081149.

6.

Machine learning-based prediction of breast cancer growth rate in vivo.

Bhattarai S, Klimov S, Aleskandarany MA, Burrell H, Wormall A, Green AR, Rida P, Ellis IO, Osan RM, Rakha EA, Aneja R.

Br J Cancer. 2019 Sep;121(6):497-504. doi: 10.1038/s41416-019-0539-x. Epub 2019 Aug 9.

PMID:
31395950
7.

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.

Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R.

Cancers (Basel). 2019 Jul 17;11(7). pii: E995. doi: 10.3390/cancers11070995.

8.

Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution.

Miligy IM, Toss MS, Khout H, Whisker L, Burrell HC, Ellis IO, Green AR, Macmillan D, Rakha EA.

Breast J. 2019 Jul 18. doi: 10.1111/tbj.13425. [Epub ahead of print]

PMID:
31318120
9.

Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles.

Agrawal U, Soria D, Wagner C, Garibaldi J, Ellis IO, Bartlett JMS, Cameron D, Rakha EA, Green AR.

Artif Intell Med. 2019 Jun;97:27-37. doi: 10.1016/j.artmed.2019.05.002. Epub 2019 May 15.

PMID:
31202397
10.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0286-9. [Epub ahead of print]

PMID:
31175327
11.

Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0296-7. [Epub ahead of print]

PMID:
31175326
12.
13.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
14.

Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions.

Green AR, Lee P, Reeve E, Wolff JL, Chen CCG, Kruzan R, Boyd CM.

J Am Board Fam Med. 2019 May-Jun;32(3):383-391. doi: 10.3122/jabfm.2019.03.180335.

15.

Investigation of the Amide Proton Solvent Exchange Properties of Glycosaminoglycan Oligosaccharides.

Green AR, Li K, Lockard B, Young RP, Mueller LJ, Larive CK.

J Phys Chem B. 2019 Jun 6;123(22):4653-4662. doi: 10.1021/acs.jpcb.9b01794. Epub 2019 May 22.

16.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

PMID:
31065110
17.

Notch Signaling Mediates Secondary Senescence.

Teo YV, Rattanavirotkul N, Olova N, Salzano A, Quintanilla A, Tarrats N, Kiourtis C, Müller M, Green AR, Adams PD, Acosta JC, Bird TG, Kirschner K, Neretti N, Chandra T.

Cell Rep. 2019 Apr 23;27(4):997-1007.e5. doi: 10.1016/j.celrep.2019.03.104.

18.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
19.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C.

Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13.

20.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL.

J Pathol. 2019 Jul;248(3):326-338. doi: 10.1002/path.5262. Epub 2019 Apr 22.

PMID:
30843206
21.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

PMID:
30816325
22.

1H NMR characterization of chitin tetrasaccharide in binary H2O:DMSO solution: Evidence for anomeric end-effect propagation.

Li K, Green AR, Dinges MM, Larive CK.

Int J Biol Macromol. 2019 May 15;129:744-749. doi: 10.1016/j.ijbiomac.2019.02.062. Epub 2019 Feb 13.

PMID:
30771389
23.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.

PMID:
30760857
24.
25.

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.

Savva C, De Souza K, Ali R, Rakha EA, Green AR, Madhusudan S.

Breast Cancer Res Treat. 2019 May;175(1):105-115. doi: 10.1007/s10549-018-05113-8. Epub 2019 Feb 12.

26.

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Nangalia J, Mitchell E, Green AR.

Blood. 2019 Mar 28;133(13):1436-1445. doi: 10.1182/blood-2018-11-835405. Epub 2019 Feb 6. Review.

PMID:
30728143
27.

The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.

PMID:
30725481
28.

Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.

Syed BM, Green AR, Morgan DAL, Ellis IO, Cheung KL.

Cancers (Basel). 2019 Jan 28;11(2). pii: E149. doi: 10.3390/cancers11020149.

29.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 May;175(1):27-38. doi: 10.1007/s10549-018-05111-w. Epub 2019 Jan 22.

PMID:
30671766
30.

Caring for Patients With Multiple Chronic Conditions.

Tinetti ME, Green AR, Ouellet J, Rich MW, Boyd C.

Ann Intern Med. 2019 Feb 5;170(3):199-200. doi: 10.7326/M18-3269. Epub 2019 Jan 22. No abstract available. Erratum in: Ann Intern Med. 2019 Mar 5;170(5):356.

PMID:
30665237
31.

Decision Making for Older Adults With Multiple Chronic Conditions: Executive Summary for the American Geriatrics Society Guiding Principles on the Care of Older Adults With Multimorbidity.

Boyd C, Smith CD, Masoudi FA, Blaum CS, Dodson JA, Green AR, Kelley A, Matlock D, Ouellet J, Rich MW, Schoenborn NL, Tinetti ME.

J Am Geriatr Soc. 2019 Apr;67(4):665-673. doi: 10.1111/jgs.15809. Epub 2019 Mar 10.

PMID:
30663782
32.
33.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Alhudiri IM, Nolan CC, Ellis IO, Elzagheid A, Rakha EA, Green AR, Chapman CJ.

Breast Cancer Res Treat. 2019 Apr;174(3):661-668. doi: 10.1007/s10549-018-05092-w. Epub 2019 Jan 4.

PMID:
30610489
34.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Apr;174(2):387-399. doi: 10.1007/s10549-018-05085-9. Epub 2018 Dec 15.

PMID:
30554343
35.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM.

Breast Cancer Res Treat. 2019 Feb;174(1):93-102. doi: 10.1007/s10549-018-5063-9. Epub 2018 Nov 24.

36.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
37.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
38.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

PMID:
30410060
39.

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Green AR, Freedman C, Tena J, Tourdot BE, Liu B, Holinstat M, Holman TR.

Biochemistry. 2018 Dec 4;57(48):6726-6734. doi: 10.1021/acs.biochem.8b00889. Epub 2018 Nov 15.

PMID:
30407793
40.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

41.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.

PMID:
30306428
42.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

43.

Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.

Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S.

Cancer Res. 2018 Dec 15;78(24):6818-6827. doi: 10.1158/0008-5472.CAN-18-0633. Epub 2018 Oct 8.

PMID:
30297533
44.

Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal.

Green AR, Aronson JK, Haddad PM.

J Psychopharmacol. 2018 Oct;32(10):1056-1066. doi: 10.1177/0269881118796810. Epub 2018 Sep 25.

PMID:
30251594
45.

Population dynamics of normal human blood inferred from somatic mutations.

Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I, Anderson E, O'Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ.

Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0. Epub 2018 Sep 5.

46.

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN; United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; and the Australasian Leukaemia and Lymphoma Group.

J Clin Oncol. 2018 Aug 28:JCO2018788414. doi: 10.1200/JCO.2018.78.8414. [Epub ahead of print]

47.

Assessing the hidden curriculum for the care of patients with limited english proficiency: An instrument development.

Green AR, Rosu C, Kenison T, Nze C.

Educ Health (Abingdon). 2018 Jan-Apr;31(1):17-24. doi: 10.4103/1357-6283.239042.

48.

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.

Sarwar M, Syed Khaja AS, Aleskandarany M, Karlsson R, Althobiti M, Ødum N, Mongan NP, Dizeyi N, Johnson H, Green AR, Ellis IO, Rakha EA, Persson JL.

Oncogene. 2019 Jan;38(3):375-389. doi: 10.1038/s41388-018-0438-2. Epub 2018 Aug 13.

49.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
50.

Impact of breast cancer grade discordance on prediction of outcome.

Rakha EA, Aleskandarany MA, Toss MS, Mongan NP, ElSayed ME, Green AR, Ellis IO, Dalton LW.

Histopathology. 2018 Dec;73(6):904-915. doi: 10.1111/his.13709. Epub 2018 Sep 19.

PMID:
29999192

Supplemental Content

Loading ...
Support Center